The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst, page-661

If it's the rights to mpl treatment of MND alone, well that's pretty good, but if it's for all uses PAA has already acquired rights and potential targets looming up like Alzheimers, then I find that it pessimistic. Surely, with the knowledge already gained and evidence already gathered in the lab including even the first phase human cancer trial years ago (the "hints" of therapeutic efficacy were already evident) any BP would be paying a premium above MND rights for a full buy out. Sure it would be a gamble on their part but it would be a calculated gamble. Anyway, that's how I see it. As for the ten dollars a share, well we need something to dream about, so let's dream a bit of blue sky - that would put the company at around 4 or so billion AUD or 2.6 billion USD, so yes, a dream, but not an unimaginable one).

(ps And I wish people would stop banging on about K9 lymphoma and Elanco, it was already evident back then to anyone who looked at the financial media that Elanco was financially struggling (and had committed itself to an alternative lymphoma treatment) and that financial situation finally manifested itself in the huge decline of its sp ).